<DOC>
	<DOCNO>NCT00286624</DOCNO>
	<brief_summary>This study design test safety efficacy 3 pancreatic alloislet transplant type 1 diabetic patient hypoglycemia unawareness . 6 subject transplant protocol use anti-thymocyte globulin induction immunosuppression everolimus cyclosporine maintenance immunosuppression .</brief_summary>
	<brief_title>Anti-Thymocyte Globulin , Cyclosporine , RAD Islet Transplantation</brief_title>
	<detailed_description>This Phase I/II study design assess safety efficacy sequential islet allotransplantation reestablishment stable glycemic control type 1 diabetic recipient . A total 6 patient type 1 diabetes receive three transplant islets different donor pancreas . Potential candidate islet allotransplantation include patient age 18 old type 1 diabetes . Induction immunotherapy first transplant consist anti-thymocyte globulin ; basiliximab use subsequent transplant . Peritransplant anti-inflammatory treatment etanercept give islet transplant . Maintenance immunosuppression cyclosporine RAD . It felt patient metabolic lability/instability , reduce awareness hypoglycemia , poor glycemic control , progressive secondary complication persist despite continued intensive effort make close cooperation diabetes care team particularly likely favorable benefit/risk ratio . Adverse event , irrespective presume relationship transplantation allogeneic islet and/or protocol-regulated treatment product ( concomitant therapy ) , monitor record throughout first year final islet transplant . The proportion single sequential donor islet allograft recipient full ( insulin independence HbA1c &lt; 7 % ) partial ( insulin dependence , basal arginine-stimulated C-peptide level great equal 0.5 ng/mL HbA1c &lt; 7 % ) islet graft function one year final islet transplant assess . The impact islet transplantation quality life also assess . The predictive value posttransplant insulin independence factor insulin resistance interval pancreatectomy , cellular composition transplant , number beta cell transplant ; viability insulin secretory response isolate islet assess .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Primary islet allotransplant Patients type 1 diabetes mellitus intensive insulin management Age 18 old Ability give write informed consent Age le 18 year . BMI &gt; 26 kg/m2 . Insulin requirement &gt; 50 IU per day . Positive Cpeptide response intravenous arginine stimulation . Untreated proliferative retinopathy . Creatinine clearance &lt; 60 ml/min/1.73 m2 females 70 ml/min/1.73 m2 male . Serum creatinine &gt; 1.3 mg/dl female , &gt; 1.5 mg/dl male . Previous pancreas islet transplant . Presence history panelreactive antiHLA antibody &gt; 10 % . Positive pregnancy test , presently breastfeed , failure follow effective contraceptive measure . Active infection include hepatitis C , hepatitis B , HIV , TB ( treatment suspect TB ) . Negative screen EpsteinBarr Virus ( EBV ) . Invasive aspergillus infection within year prior study entry . History malignancy . Active alcohol substance abuse History nonadherence prescribe regimen . Psychiatric disorder make subject suitable candidate transplantation . Inability provide inform consent . Baseline Hgb &lt; 11.7 g/dl female , &lt; 13 g/dl male ; lymphopenia ( &lt; 1,000/microL ) , leukopenia ( &lt; 3,000 total leukocytes/microL ) , absolute CD4+ count &lt; 500/microL. , platelet &lt; 150,000/microL History coagulopathy medical condition require longterm anticoagulant therapy transplantation patient INR &gt; 1.5 . Severe coexist cardiac disease . Baseline liver function test outside normal range history significant liver disease . Active peptic ulcer disease . Severe unremitting diarrhea gastrointestinal disorder potentially interfere ability absorb oral medication . Presence severe allergy require acute chronic treatment , hypersensitivity drug similar RAD ( e.g. , macrolides ) . Known hypersensitivity rabbit protein . Hyperlipidemia ( fast LDL cholesterol &gt; 130 mg/dl , treat untreated ; and/or fast triglyceride &gt; 200 mg/dl ) . Addison 's disease . Under treatment require chronic use systemic steroid . Any medical condition , opinion investigator , interfere safe completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>